← Leaderboards
Robert A Branch
University Of Pittsburgh At Pittsburgh
$5,498,174
Attributed
$5,998,174
Total exposure
15
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,998,174 · 15
By mechanism
R01$3,225,682 · 2
P50$1,399,969 · 1
RC4$1,000,000 · 1
M01$372,523 · 11
Top collaborators
- Ann L. Chester1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Richard D Wood$10,078,142
- Michael W Epperly$5,121,193
- Robert S. Clark$12,893,742
- Shivendra Singh$26,555,479
- Jeremy N Rich$24,023,429
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectDrug MetabolismEnzyme ActivityPatient Oriented ResearchDrug Screening /EvaluationHuman Therapy EvaluationClinical Trial Phase ICombination ChemotherapyPharmacokineticsCytochrome P450BaseEducational AspectsResourcesMetricInformation TechnologyResearch InfrastructureUniversitiesData ManagementData MiningBasic ScienceAnalgesicsInformation SystemsFunding
Grant awards (39)
INFORMATION TECHNOLOGY AND BIOSTATISTICS CORE$274,328
P50 · FY2012 · HL · contact PI
Community Appalachian Investigation and Research Network (CAIRN)$1,000,000
RC4 · FY2010 · RR · contact PI
INFORMATION TECHNOLOGY AND BIOSTATISTICS CORE$274,553
P50 · FY2010 · HL · contact PI
INFORMATION TECHNOLOGY AND BIOSTATISTICS CORE$274,354
P50 · FY2009 · HL · contact PI
INFORMATION TECHNOLOGY AND BIOSTATISTICS CORE$269,184
P50 · FY2008 · HL · contact PI
INFORMATION TECHNOLOGY AND BIOSTATISTICS CORE$307,550
P50 · FY2007 · HL · contact PI
Drug Metabolism and Chronic Liver Disease$430,605
R01 · FY2005 · DK
IMPLICATION GENETIC POLYMORPHISMS DRUG METAB ENZYMES PHENOTYPIC IN NORMAL SUBJ$112,588
M01 · FY2005 · RR
LEVELS OF SELECTED POTENTIALLY CARCINOGENIC DRINKING WATER DISINFECTION$55,294
M01 · FY2005 · RR
SCREENING FOR DRUG METABOLIZING ENZYME STUDIES$44,636
M01 · FY2005 · RR
EFFECT OF LIVER DISEASE ON DRUG METABOLIZING ENZYMES$22,317
M01 · FY2005 · RR
DRUG METABOLISM AND CHRONIC LIVER DISEASE$15,322
M01 · FY2005 · RR
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJ$3,664
M01 · FY2005 · RR
VALIDATION OF MODIFIED PITTSBURGH COCKTAIL STUDY$1,999
M01 · FY2005 · RR
Drug Metabolism and Chronic Liver Disease$420,008
R01 · FY2004 · DK
DRUG METABOLIZING ENZYMES-RISK FACTORS IN BLADDER CANCER$406,508
R01 · FY2004 · CA
Genetic Polymorphisms in Drug Metabolism Enzymes$50,112
M01 · FY2004 · RR
Screening for Drug Metabolizing Enzyme Studies$29,762
M01 · FY2004 · RR
Effect of Liver Disease on Drug Metabolizing Enzymes$11,701
M01 · FY2004 · RR
Within Subj. Variability in Measurements Drug Metabol.$10,684
M01 · FY2004 · RR
Drug Metabolism and Chronic Liver Disease$5,342
M01 · FY2004 · RR
Drug Metabolism and Chronic Liver Disease$410,832
R01 · FY2003 · DK
DRUG METABOLIZING ENZYMES-RISK FACTORS IN BLADDER CANCER$395,999
R01 · FY2003 · CA
Drug Metabolism and Chronic Liver Disease$400,204
R01 · FY2002 · DK
DRUG METABOLIZING ENZYMES-RISK FACTORS IN BLADDER CANCER$385,755
R01 · FY2002 · CA
PH I STUDY TO ASSESS SAFETY &TOLERABILITY OF LICOSTINEL$0
M01 · FY2002 · RR
ORAL LY333013 AND METHOTREXATE DRUG INTERACTIONS STUDY$0
M01 · FY2002 · RR
ORAL LY333013 AND METHOTREXATE DRUG INTERACTIONS STUDY$0
M01 · FY2002 · RR
PH I STUDY TO ASSESS SAFETY &TOLERABILITY OF LICOSTINEL$0
M01 · FY2002 · RR
DEVELOPMENT OF FLURBIPROFEN AS A SELECTIVE PROBE OF CYP2C9$0
M01 · FY2002 · RR
DEVELOPMENT OF FLURBIPROFEN AS A SELECTIVE PROBE OF CYP2C9$0
M01 · FY2002 · RR
DRUG METABOLIZING ENZYMES-RISK FACTORS IN BLADDER CANCER$375,771
R01 · FY2001 · CA
DEVELOPMENT OF FLURBIPROFEN AS A SELECTIVE PROBE OF CYP2C9$0
M01 · FY2001 · RR
ORAL LY333013 AND METHOTREXATE DRUG INTERACTIONS STUDY$0
M01 · FY2001 · RR
PH I STUDY TO ASSESS SAFETY &TOLERABILITY OF LICOSTINEL$0
M01 · FY2001 · RR
PH I STUDY TO ASSESS SAFETY &TOLERABILITY OF LICOSTINEL$3,034
M01 · FY2000 · RR
DEVELOPMENT OF FLURBIPROFEN AS A SELECTIVE PROBE OF CYP2C9$3,034
M01 · FY2000 · RR
DOES QUININE HAVE ANALGESIC EFFECTS--STUDY OF PATIENT WITH LOW BACK PAIN$3,034
M01 · FY2000 · RR
ORAL LY333013 AND METHOTREXATE DRUG INTERACTIONS STUDY$0
M01 · FY2000 · RR